Posted by Michael Wonder on 22 Aug 2022
TGA grants provisional determination for sabizabulin for the treatment of COVID-19
22 August 2022 - On 19 August 2022, the TGA granted a provisional determination to Adjutor Healthcare for a new orally-administered medicine, sabizabulin for treatment of COVID-19.
The determination means that Adjutor Healthcare is now able to apply for provisional registration of sabizabulin for treatment of SARS-CoV-2 infection in hospitalised patients with moderate-to-severe COVID-19 infection and at high risk of developing Acute Respiratory Distress Syndrome and becoming seriously ill.
